According to a new report from Intel Market Research, the global Pembrolizumab market was valued at USD 21.8 billion in 2025 and is projected to grow from USD 24.3 billion in 2026 to USD 42.7 billion by 2034, exhibiting a robust CAGR of 7.3% during the forecast period. This growth is driven by increasing cancer prevalence, rising immunotherapy adoption, expanding regulatory approvals for new...